Purpose
The aim of this document is to provide information on the preparation and quality control of white blood cells (WBC) labelled with
99mTc-exametazime (
99mTc-hexamethylpropyleneamine oxime;
99mTc-HMPAO) that can assist nuclear medicine practitioners, radiopharmacists, technicians and other individuals involved. The corresponding guidelines of the Society of Nuclear Medicine, the consensus protocol of the International Society of Radiolabelled Blood Elements (ISORBE), recommendations of the International Atomic Energy Agency, several national guidelines, and the most relevant literature were taken into consideration and were partially integrated into this text [
1‐
21]. The present guidelines, therefore neither arise from a consensus conference nor from an evidence-based meta-analysis, but were produced by a panel of experts based on data from peer-reviewed literature, as well as their own experience and knowledge of colleagues from all over the world that was shared at meetings, at congresses and during collaborative scientific work including multicentre studies.
Different European countries have different recommendations and laws regarding the specific matter of production of extemporaneous radiopharmaceuticals, in particular when labelled autologous cells are considered, since they cannot be sterilized after synthesis. We performed a survey in Europe, to which the national delegates of 14 countries officially replied and four others contributed verbally. The results of this survey are summarized in Table
1 and demonstrate overall that WBC labelling is a well-established technique in Europe, and is mainly performed by trained personnel under sterile conditions in a laminar flow cabinet (class A). However, the requirements for the environment in which the flow cabinet is located vary greatly among countries. Thus, different rules apply among the European countries.
Table 1
Results of a survey about WBC labelling amongst the national delegates of the EANM
Range 0–66.7% | By law, 5% (1) | Nuclear physicians, 5% (1) | Class-A hood, 22% (4) |
Mean 32.6% | Recommendations, 67% (12) | Radiopharmacists, 16% (3) | Class A hood in B, 28% (5) |
SD 23.9% | Conform to cGRPP, 17% (3) | Pharmacists, 11% (2) | Class A hood in C, 16% (3) |
Median 41.4% | No rules, 27% (5) | Trained personnel, 55% (10) | Class A hood in D, 16% (3) |
| | No rules, 16% (3) | No rules, 11% (2) |
This protocol aims to guide labelling of WBC in accordance with currently effective European Union regulations. In addition, the specific rules in various countries must be complied with. The procedure may therefore have to be adjusted to local rules, needs and the equipment available.
Scintigraphy with labelled autologous WBCs is a widely used method to detect sites of infection. In the mid 1970s,
111In-oxine was introduced as a nonselective labelling agent for WBC scintigraphy. Although
111In-oxine-labelled WBC have been successfully used in the field of infection/inflammation scintigraphy, over the years the labelling agent has been largely replaced by
99mTc-HMPAO, because of the favourable physical characteristics, availability, cost and lower radiation burden (Table
2) of
99mTc as compared with
111In. Since
111In-oxine-labelled WBC are still in use in several centres and for specific clinical indications, the labelling procedure of WBC with this radiopharmaceutical are covered in separate guidelines.
Table 2
Radiation dosimetry for 99mTc-HMPAO labelled leucocytes
Adults | 185–370 | 0.15 | 0.011 |
Children (5 years old) | 3.7–7.4/kg | 0.48 | 0.034 |
99mTc-HMPAO kit preparations have been commercially available since 1988. Upon reconstitution of the HMPAO kit (containing both d-and l-isomers) with 99mTc-pertechnetate from a fresh generator eluate (preferably within 30 min of elution) a lipophilic complex is formed. The lipophilic complex is transformed into free 99mTc-pertechnetate and a hydrophilic 99mTc-HMPAO complex in aqueous solution over time. Only freshly prepared 99mTc-HMPAO should therefore be used for leucocyte labelling (within 20 min of preparation) since only the lipophilic 99mTc-HMPAO complex can freely cross the cell membrane of WBC and is subsequently trapped inside the cell.
Two mechanisms have been suggested to be responsible for the retention of 99mTc-HMPAO inside the cell: (1) conversion of the lipophilic 99mTc-HMPAO complex into a hydrophilic complex by reducing agents such as glutathione, and (2) binding of 99mTc-HMPAO to nondiffusible proteins and cell organelles. Some release of 99mTc-HMPAO from the labelled WBC after reinjection into the patient is observed, resulting in undesired accumulation of radioactivity in the gastrointestinal and urinary tracts. For WBC scintigraphy, either mixed leucocytes or isolated granulocytes can be used. When mixed leucocytes are labelled with 99mTc-HMPAO, about 70–80% of the radioactivity is bound to granulocytes. Labelled mixed leucocytes can display higher blood pool activity than labelled isolated granulocytes, especially in early images, due to the presence of labelled lymphocytes and residual erythrocytes.
Common indications for 99mTc-HMPAO WBC scintigraphy
99mTc-HMPAO-labelled WBC scintigraphy may be used to detect and localize any occult site of infection and to determine the extent of the process in various disorders, including:
-
Osteomyelitis of the appendicular skeleton
-
Infected joint and vascular prosthesis
-
Diabetic foot
-
Fever of unknown origin
-
Postoperative abscesses
-
Lung infections
-
Endocarditis
-
Inflammatory bowel disease
-
Neurological infections
-
Infected central venous catheters or other devices
Inflammatory bowel disease and kidney infections are better imaged with 111In-oxine-labelled WBC, because of the lower release of the radiopharmaceutical and its metabolites from labelled cells, resulting in lower nonspecific gastrointestinal and urinary tract activity.
Precautions
During the labelling procedure, blood and blood components from the patient, who could potentially be infected with pathogens, need to be handled. To prevent contamination of the operator who is performing the labelling, waterproof gloves should be worn throughout the procedure. Special caution should be taken when handling needles.
Since 99mTc-HMPAO-labelled WBC have to be reinjected into the patient, strict aseptic conditions are required for the labelling procedure. For this purpose, only sterile reagents and disposable plastic-ware should be used, and sterile gloves, cap and mask should be worn. Usually, the labelling of WBC is performed in a laminar flow cabinet or cell isolator, installed according to local regulations. Recently, certified sterile closed-kit labelling devices have become available that may represent a good approach to WBC labelling with further protection for patient and operator, despite the fact that they have to be used in a sterile cabinet as well.
Simultaneous labelling of WBC from multiple patients is discouraged in order to prevent possible cross-contamination. Labelling of WBC from different patients should be carried out at physically separated locations unless closed devices are used. At all times correct identification of the patient’s blood products should be guaranteed. All syringes, tubes and any material in contact with the patient’s blood components should be clearly labelled with the patient’s name, bar-code and/or colour code.
During the labelling of WBC with 99mTc-HMPAO care should be taken that leucocytes are not damaged, as this would result in leakage of the radioactivity from the cells, adhesion of labelled leucocytes to the vascular endothelium (especially in the microvasculature of the lungs) and loss of motility. To avoid degradation of the radiopharmaceutical and radiation damage to labelled cells, 99mTc-HMPAO-labelled WBC should be reinjected as soon as possible, but not later than 1 h after labelling.
Labelling of mixed leucocytes causes radiation damage to the lymphocytes as a result of self-irradiation by low-energy Auger electrons. However, since the lymphocytes are unable to divide after labelling and are eliminated through apoptosis and phagocytosis, the risk of lymphoid malignancies after administration of 99mTc-HMPAO-labelled mixed leucocytes is considered to be negligible.
Procedure
B. Labelling of WBCs with 99mTc-HMPAO
Prepare 99mTc-HMPAO using freshly eluted 99mTc-pertechnetate. Do not use a stabilizing agent (methylene blue, cobalt) or PBS in the preparation of 99mTc-HMPAO. Because 99mTc-HMPAO is unstable in aqueous solutions, the radiopharmaceutical should be prepared immediately before use. Periodically, perform quality control of the 99mTc-HMPAO preparation according to the procedure described by the manufacturer in the accompanying leaflet. Add 1 ml of freshly prepared 99mTc-HMPAO (approximately 750–1,000 MBq) in saline solution to the mixed leucocyte cell suspension (or purified granulocytes) and incubate for 10 min at room temperature. Although the package insert of HMPAO (Ceretec; GE Healthcare, Little Chalfont, UK) indicates that 99mTc-HMPAO should be prepared in 5 ml and that the whole dose should be used for a single labelling, there is enough scientific evidence to support the use of smaller volumes of 99mTc-HMPAO that result in higher LE. During incubation, gently swirl the cell suspension periodically to prevent sedimentation of the cells. After the incubation is complete, add at least 3 ml (preferably up to 10 ml) of CFP, and centrifuge at 150 g for 5 min. If necessary, additional CFP can be obtained by centrifugation of the PRP (step A3) at 2,000 g for 10 min. Alternatively, PBS or saline could be used instead of CFP. After centrifugation, remove the supernatant containing unbound 99mTc-HMPAO and measure the amount of radioactivity in the pellet and in the supernatant to calculate the LE. Gently resuspend the pellet containing the labelled mixed leucocytes in 3–5 ml of CFP. Dispense the patient dose (recommended dose 370–740 MBq) from the cell suspension. The 99mTc-HMPAO-labelled WBC should be visually inspected and reinjected into the patient as soon as possible, and not later than 1 h after completion of the labelling procedure. Injection of the labelled WBC should be performed slowly, preferably using a needle of at least 22 G (0.7 mm diameter) to prevent cell damage due to shear stress (the inner diameter of the needle is only approximately 50-fold larger than the diameter of the WBC). Check the patient’s identity prior to administration of the labelled WBC.
C. Quality controls
Several methods for quality control have been described, although only a few of them are used regularly in clinical routine, as many of these tests are time-consuming. For routine clinical use, visual inspection of the final product and determination of the LE are usually considered sufficient. Microscopic inspection of clumping, the trypan blue exclusion viability test and the post-release sterility test could be used as additional quality controls, when desired. These tests should be included when setting the methodology for its validation and when a new variation in the method is introduced. Early in vivo lung uptake and liver-to-spleen activity ratio are the most commonly used in vivo indices of quality control. For process validation, operator validation or periodic process control, additional functional tests such as chemotaxis or phagocytosis assays may be included, but these are not recommended for routine use.
Methodological issues requiring further clarification
-
The optimal formulation of HES plasma expander and the value of alternatives such as succinylated gelatin and methyl cellulose.
-
The use of low-speed centrifugation instead of sedimentation to separate LRP from red blood cells.
-
The added value of an optional additional centrifugation step to reduce the amount of contaminating platelets before labelling.
-
The use of PBS or saline as an alternative to CFP as the medium for cell labelling and resuspension.
-
The use of PRP instead of CFP, PBS or saline for centrifugation after labelling.
-
The use of PBS as an alternative to CFP for reconstitution of labelled WBC.
-
The need for gradient centrifugation and the availability of GMP grade gradient solutions for granulocyte purification.
-
Qualification and training required for personnel who perform WBC labelling.
-
Requirements for equipment and infrastructure for WBC labelling.
Closed disposable sterile systems for WBC labelling
The recent availability of a closed disposable sterile system (Leukokit; GE Healthcare, Little Chalfont, UK) for WBC separation and labelling offers an additional advantage for operator protection and for avoiding sample contamination. It is a licensed medical device distributed worldwide that may allow simplification of the required infrastructure, although to date there is no defined legislation for the use of this type of product in a different way from that of open systems. The kit includes a sterile GMP-produced vial of anticoagulant agent (ACD-A), a vial of 10% HES and a vial of PBS for cell washing and resuspension, thus avoiding possible causes of contamination of the labelled product.
Procedure and personnel validation
The WBC labelling process must be simulated for validation of the process prior to starting clinical studies in a specific laboratory. It is recommended that the requirements for the validation procedure are more strict than those for regular quality control. The validation procedure should include control of LE (>50%), sterility test (negative), pyrogenicity (absent), viability of cells (>98%), cell subset recovery test (in final cell suspension erythrocyte/WBC ratio <3) and measurement of in vitro cell efflux of 99mTc within the first hour after labelling (<10%). Sterility tests can be done with media fills or using different culture media. Tests may vary considerably and may include bacterial growth medium (e.g. agar) plates for environmental monitoring as well as hand-wash plates for hand-wash validation.
Procedure and personnel validation should be performed at least three times for each new operator prior to initiation of clinical studies and should be repeated at regular intervals (suggested every 6 months) and after any significant change in the method or reagents.
Acknowledgments
The Taskgroup of the EANM on Infection/Inflammation Imaging would like to thank the following colleagues: Marco Chianelli, Dante D′Oppido, Paola Erba, Elena Lazzeri, Napoleone Prandini and Anna Laura Viglietti from the AIMN study group on Inflammation/Infection, and Alain Faivre-Chauvet and Clemens De Cristoforo from the EANM Radiopharmacy Committee for their collaboration in the preparation of these guidelines, and their contribution through useful discussions and suggestions. We also thank Lori Camillo-Sforza for manuscript editing and administrative assistance and the ISORBE Presidium for useful suggestions.
Open AccessThis is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (
https://creativecommons.org/licenses/by-nc/2.0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.